DCDorian Chastagner

Dorian Chastagner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorian Chastagner has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preemptive Pharmacogenetics in Renal Transplantation: A Real-World Assessment of Pharmacogenetic Actionability

    by Dorian Chastagner, Hélène Arnion, Caroline Monchaud, Jean-Philippe Rérolle, Clément Danthu, Fatouma Touré, Nicolas Picard

    Background: Pharmacogenetics (PGx) is increasingly recognized as an important component of personalized medicine. In kidney transplantation, where immunosuppressive therapies and comedications often have narrow therapeutic index, preemptive PGx could complement therapeutic drug monitoring to improve individualized care. This study aimed to investigate the value of implementing PGx testing in the pretransplant assessment of renal transplant recipients. Methods: This single-center retrospective study included 110 adult patients who underwent a pretransplant PGx assessment between January 1, 2022, and June 30, 2023. The analysis focused on 16 pharmacogenes shared between the local routine PGx panel and the publicly available ClinPGx guideline support interface, with some genes analyzed using hotspot-only coverage. Medication lists were extracted at 2 time points: pretransplant and post-transplant (or last follow-up for patients on waiting list). Theoretical actionability was defined as the presence of at least 1 actionable genotype, and effective actionability as at least 1 actionable gene–drug pair according to international guidelines. Results: Theoretical actionability was observed in 109 of 110 patients (99%). Effective actionability concerned 29 of 110 patients (26%) at the pretransplant assessment and 19 of 41 (46%) at the post-transplant stage. The most frequent actionable gene–drug pairs at the latter stage included CYP2C19- proton pump inhibitors (38%), CYP3A5 -tacrolimus (25%), SLCO1B1- statins (13%), CYP2D6-tramadol (8%), and ABCG2 -allopurinol (8%). Conclusions: Preemptive PGx embedded in the pretransplant evaluation identifies clinically relevant gene–drug interactions. In combination with therapeutic drug monitoring, this approach has the potential to optimize immunosuppressive drugs initiation and support pharmacological management in kidney transplantation.

  • Open Access

    Advances in organ-on-chip for drug transporter study: Key insights and hurdles

    by Isy Petit, Jean-Sébastien Bernard, Quentin Faucher, Dorian Chastagner, Hélène Arnion, Florent Di Meo, Nicolas Védrenne


  • Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions

    by Dorian Chastagner, Hélène Arnion, Clément Danthu, Fatouma Touré, Nicolas Picard

    Posttransplantation diabetes mellitus (PTDM) is a form of diabetes developed after solid organ or stem cell transplantation. This condition shares physiopathological traits with type 2 diabetes, including insulin resistance and β-cells dysfunction and its prevalence varies significantly based on the diagnostic criteria used. Immunosuppressive drugs directly contribute to PTDM risk through intricate impacts on glucose regulation, insulin secretion, and inflammation. In addition, modifiable and non-modifiable environmental risk factors are associated with the onset of this condition. This review aims to provide a comprehensive overview of the multifactorial nature of PTDM in order to highlight candidate genes and variants for pharmacogenetic research. An extensive literature search was conducted to identify studies on pharmacological and genetic factors influencing PTDM development. This review stresses the importance of understanding these interactions for improving PTDM management and underscores the need for further research to refine preventive approaches, ultimately enhancing patient outcomes post-transplantation.